10.30 | 7.40 – Liquid Lessons Learned From 2020 – Regulatory, Supply Chain, Payer & The Patients

Time: 10:30 am
day: Day Three


  • Reflecting on recent FDA approvals– What are the key regulatory considerations for liquid biopsy
    companion diagnostic tests?
  •  Liquid biopsy application is making signification contribution in cancer care seen by patients, but what challenges need to be overcome and knowledge gaps filled to support future liquid biopsy applications?
  •  What can we learn from recent supply chain disruptions resulting from the coronavirus pandemic to reduce delays in diagnostics reaching patients
  • Tying together key considerations for liquid biopsy development and integration into therapeutic
    programmes, and the importance of keeping regulatory, supply chain, payer & the patient  priorities front of mind from the beginning